Previous 10 | Next 10 |
Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...
DURHAM, N.C., July 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the commercial availability of DOPTELET (av...
Dova Pharmaceuticals ( DOVA ) was founded in 2016, and is based in Durham, North Carolina. In this article, I will analyze Dova’s product pipeline and present my investment thesis for this company. The company’s lead product is Doptelet (avatrombopag), an oral, thrombopoietin r...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Dova Pharmaceuticals ( DOVA ) was able to obtain FDA approval for its supplemental New Drug Application ((NDA)) for Doptelet for adults with chronic immune thrombocytopenia ((ITP)). This expands upon the label to its first approval of Doptelet for patients with chronic liver disease ((CLD)...
Evercore ISI has upgraded Dova Pharmaceuticals (NASDAQ: DOVA ) to Outperform, from In-Line. More news on: Dova Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Evercore ISI has upgraded Dova Pharmaceuticals (NASDAQ: DOVA ) to Outperform, from In-Line. More news on: Dova Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: Cemtrex (NASDAQ: CETX ) +120% . The Howard Hughes (NYSE: HHC ) +38% . J.Jill (NYSE: JILL ) +21% . Foresight Autonomous Holdings (NASDAQ: FRSX ) +21% . Zogenix (NASDAQ: ZGNX ) +21% . Herman Miller (NASDAQ: MLHR ) +18% . Atossa Genetics (NASDAQ: ATOS ) +16% . Dova...
Dova Pharmaceuticals (NASDAQ: DOVA ) +32% as FDA OKs Dova's Doptelet for low blood platelets in ITP patients. More news on: Dova Pharmaceuticals, Inc., Atossa Genetics Inc., Zogenix, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Dova Pharmaceuticals Inc. Company Name:
DOVA Stock Symbol:
NASDAQ Market:
Dova Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / October 30, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Jagged Peak Energy Inc ( JAG ) related to...
NEW YORK, NY / ACCESSWIRE / October 19, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . ( RARX ) related to i...
NEW YORK / ACCESSWIRE / October 17, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . (NASDAQ: RARX ) relate...